Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
It may go without saying, but the old-fashioned way diet and exercise remains a preferred weight loss method
These typically resolve within the first week
CAS 2381089-83-2 CAS No
This gave me more freedom, or a bridge, if you will, to balance hormones
Maintenance may include continued medication, dose adjustment, nutrition support, strength training, metabolic monitoring, and follow-up visits
